Dr. Elizabeth Race

Dr. Elizabeth Race

Dr. Elizabeth Race

Dr. Elizabeth Race

Learn More
About Me

I am the Doctor of the AHF Healthcare Center – Dallas. I was fortunate in being able to participate in the field of HIV Medicine in South Africa with the Foundation for Professional Development, through the auspices of Global Medic Force – a non-profit HIV Medicine specialty organization. The international breadth of the HIV epidemic has been devastating for over 30 years now, and AIDS Healthcare Foundation is unique in that this organization has a strong presence both in the United States and around the world – where providing HIV medications & care remain critical.

Fun Fact: Native Texan with an emphasis on Spanish. Followed my lifetime interest in International Health and Tropical Medicine / Parasitology to the London School of Tropical Medicine and Hygiene for a course on the Laboratory Identification of Parasites.

About the AHF Healthcare Center – Dallas

The Dallas office is filled with great employees that strive to deliver our mission everyday: providing cutting-edge medicine and advocacy regardless of ability to pay. These clinics are an accepting place to patients from all backgrounds where anybody can feel welcome. We strive to meet the needs of our patients so they can live happy and productive lives.

Medical Groups & Plans

We accept – Ryan White and many insurance plans, please call to validate yours.

Training, Certifications, and Licensing
MEDICAL SCHOOL

University of Texas, MD.

GRADUATE SCHOOL

Master of Medical Sciences in Clinical Investigation
Harvard University

Master of Public Health
Harvard School of Public Health

CERTIFICATIONS

American Academy of HIV Medicine
HIV Specialist

MEDICAL TRAINING

Years in Practice 
29

License Information
License Issuing State
Texas

Residency
Internship in Internal Medicine
University of Texas Southwestern Medical Center at Dallas

Residency in Internal Medicine
University of Texas Southwestern Medical Center at Dallas

Fellowships
Fellowship in Infectious Diseases
Harvard Combined Infectious Disease Training Program
Boston, MA

Fellowship in HIV Medicine
Harvard Combined Infectious Disease Training Program
Boston, MA

AWARDS/RECOGNITIONS

Acted as a Sub-Investigator for multiple ACTG Network as well as industry clinical trials:

An International, Multicenter, Prospective Observational Study of the Safety of Maraviroc used with Optimized Background Therapy in Treatment-Experienced HIV-1 Infected Patients

Protocol A4001078: Pilot Study of Novel Combination of Maraviroc + Atazanavir/Ritonavir Versus. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Treatment Naïve HIV-Infected Patients With R5 HIV-1

Protocol A4001080: A Multicenter, Randomized, Open, Comparative Trial of Maraviroc Versus Etravirine Each in Combination with Darunavir/Ritonavir and Raltegravir for the Treatment of Antiretroviral-Experienced HIV-1 Subjects Co-Infected with Hepatitis C and/or Hepatitis B

Protocol 1100.1486: A randomized, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapinE immediate release in combination with Truvada® in antiretroviral therapy naïve HIV-1 infected patients (VERVE)

Protocol P04875: Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects

Protocol P05241: Effect of Vicriviroc on HIV RNA levels in Cerebrospinal Fluid

PUBLICATIONS/PRESENTATIONS

Glesby MJ, Bassett R, Alston-Smith B, Fichtenbaum C, Jacobson EL, Brass C, Owens S, Sulkowski M, Race EM, Sherman KE. AIDS Clinical Trials Group A5088 Protocol Team. Pilot Study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection. J Infec Dis, 191(5):686-93; 2005 Mar 1.

Shulman N, Zolopa A, Havlir D, Gallant J, Race E, Sun E and Kempf D. The Virtual Inhibitory Quotient Predicts the Response to Ritonavir Boosting of Indinavir-Based Therapy in HIV-1 Infected Patients with Ongoing Viremia. Antimicrobial Agents and Chemotherapy 2002; 46(12):3907-16.

Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL and Japour AJ. Focal Mycobacterial Lymphadenitis Following Initiation of Protease Inhibitor Therapy in Patients with Advanced HIV-1 Disease. Lancet 1998; 351:252-5.

Harrich D, Hsu C, Race EM and Gaynor RB. Differential growth kinetics are exhibited by human immunodeficiency virus type I TAR mutants. J Virology 1994; 68: 5899-910.

Race EM, Ramsey KM, Lucia HL and Cloyd NM. HIV infection elicits early antibody not detected by standard tests: Implications for diagnostics and viral immunology. Virology 1991; 184: 716-22.

Reid TR, Race ER, Wolfe BR, Friedman RM, Merigan TC and Basham TY. Enhanced in vivo therapeutic response to interferon in mice with an in vitro interferon-resistant B cell lymphoma. Cancer Research 1989; 49: 4163-69.

Basham TY, Race ER, Campbell MJ, Reid TR, Levy R and Merigan TC. Synergistic antitumor activity with interferon and monoclonal anti-idiotype for murine B cell lymphoma. J Immunology 1988; 141: 2855-60.

Invited Articles

Race E, Berthelot C and Cather JC. Dermatology Report: Painful Nodule with Induration and Spreading Erythema (Community-Acquired Methicillin-Resistant Staphylococcus aureus CA-MRSA). Baylor University Medical Center Proceedings 2005; 18(4): 401-4.

Race E and Vance E. Unusual Infections in Oncology: Strongyloidiasis. Infections in Oncology 2000; 4 (3): 6-8 .

Vance E and Race E. Unusual Infections in Oncology: Coccidioidomycosis. Infections in Oncology 2000; 4 (1): 5-8.

Abstracts

Hsu A, Zolopa A, Shulman N, Havlir D, Gallant J, Race E, Jiang P, Boller S, Swerdlow J, Jasinsky O, Renz C, Japour AJ, Kempf D and Sun E. Final analysis of Ritonavir (RTV)
Kempf D, Hsu A, Jiang P, Rode R, Hertogs K, Larder B, Zolopa A, Shulman N, Havlir D, Gallant J, Race E, Boller S, Swerdlow J, Jasinsky O, Renz C and Sun E. Response to Ritonavir (RTV) Intensification in Indinavir (IDV) Recipients Is Highly Correlated with Virtual Inhibitory Quotient. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 2000; Program and Abstracts:176 ( abstract no. 523).

Shulman N, Zolopa A, Havlir D, Gallant J, Race E, Lam W, Hill A, Japour A, Kempf E, Sun E and Hsu A. Ritonavir Intensification in Indinavir Recipients with Detectable HIV RNA Levels. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 2000; Program and Abstracts: 176 (abstract no. 534).
Ritonavir Boosting of Indinavir-Based Therapy in HIV-1-infected Patients With Ongoing Viremia. International Workshop on HIV Drug Resistance & Treatment Strategies, June 12-16, 2000; abstract 95.

Ritonavir Boosting of Indinavir-Based Therapy in HIV-1-infected Patients With Ongoing Viremia. 13th World AIDS Conference, Durban, S. Africa, July 2000.

Ritonavir Boosting of Indinavir-Based Therapy in HIV-1-Infected Patients With Ongoing Viremia. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands; April 2-4, 2001; abstract 7.3.

Race E, Adelson-Mitty J, Barlam T and Japour A. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease inhibitor (PRI) in Patients with Advanced HIV-1 Disease. 4th Conference on Retroviruses and Opportunistic Infections, Washington D.C., 1997; Program and Abstracts: 129 (abstract no. 352).

Race E, Reimann K, Letvin N and Japour A. Recurrence of Trimethoprim-Sulfamethoxazole (TMP-SMX) Hypersensitivity Following Initiation of Protease Inhibitor (PRI) in Patients with Advanced HIV-1. 4th Conference on Retroviruses and Opportunistic Infections, Washington D.C., 1997; Program and Abstracts: 164 (abstract no. 535).



Love what you see?
Meet more of our amazing staff! Just scroll below.

Dr. Elizabeth Race

Dr. Elizabeth Race

About Me

I am the Doctor of the AHF Healthcare Center – Dallas. I was fortunate in being able to participate in the field of HIV Medicine in South Africa with the Foundation for Professional Development, through the auspices of Global Medic Force – a non-profit HIV Medicine specialty organization. The international breadth of the HIV epidemic has been devastating for over 30 years now, and AIDS Healthcare Foundation is unique in that this organization has a strong presence both in the United States and around the world – where providing HIV medications & care remain critical.

Fun Fact: Native Texan with an emphasis on Spanish. Followed my lifetime interest in International Health and Tropical Medicine / Parasitology to the London School of Tropical Medicine and Hygiene for a course on the Laboratory Identification of Parasites.

About the AHF Healthcare Center – Dallas

The Dallas office is filled with great employees that strive to deliver our mission everyday: providing cutting-edge medicine and advocacy regardless of ability to pay. These clinics are an accepting place to patients from all backgrounds where anybody can feel welcome. We strive to meet the needs of our patients so they can live happy and productive lives.

Medical Groups & Plans

We accept – Ryan White and many insurance plans, please call to validate yours.

Training, Certifications, and Licensing
MEDICAL SCHOOL

University of Texas, MD.

GRADUATE SCHOOL

Master of Medical Sciences in Clinical Investigation
Harvard University

Master of Public Health
Harvard School of Public Health

CERTIFICATIONS

American Academy of HIV Medicine
HIV Specialist

MEDICAL TRAINING

License Information
License Issuing State
Texas

Years in Practice 
29

Residency
Internship in Internal Medicine
University of Texas Southwestern Medical Center at Dallas

Residency in Internal Medicine
University of Texas Southwestern Medical Center at Dallas

Fellowships
Fellowship in Infectious Diseases
Harvard Combined Infectious Disease Training Program
Boston, MA

Fellowship in HIV Medicine
Harvard Combined Infectious Disease Training Program
Boston, MA

AWARDS/RECOGNITION

Acted as a Sub-Investigator for multiple ACTG Network as well as industry clinical trials:

An International, Multicenter, Prospective Observational Study of the Safety of Maraviroc used with Optimized Background Therapy in Treatment-Experienced HIV-1 Infected Patients

Protocol A4001078: Pilot Study of Novel Combination of Maraviroc + Atazanavir/Ritonavir Versus. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Treatment Naïve HIV-Infected Patients With R5 HIV-1

Protocol A4001080: A Multicenter, Randomized, Open, Comparative Trial of Maraviroc Versus Etravirine Each in Combination with Darunavir/Ritonavir and Raltegravir for the Treatment of Antiretroviral-Experienced HIV-1 Subjects Co-Infected with Hepatitis C and/or Hepatitis B

Protocol 1100.1486: A randomized, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapinE immediate release in combination with Truvada® in antiretroviral therapy naïve HIV-1 infected patients (VERVE)

Protocol P04875: Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects

Protocol P05241: Effect of Vicriviroc on HIV RNA levels in Cerebrospinal Fluid

PUBLICATIONS/PRESENTATIONS

Glesby MJ, Bassett R, Alston-Smith B, Fichtenbaum C, Jacobson EL, Brass C, Owens S, Sulkowski M, Race EM, Sherman KE. AIDS Clinical Trials Group A5088 Protocol Team. Pilot Study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection. J Infec Dis, 191(5):686-93; 2005 Mar 1.

Shulman N, Zolopa A, Havlir D, Gallant J, Race E, Sun E and Kempf D. The Virtual Inhibitory Quotient Predicts the Response to Ritonavir Boosting of Indinavir-Based Therapy in HIV-1 Infected Patients with Ongoing Viremia. Antimicrobial Agents and Chemotherapy 2002; 46(12):3907-16.

Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL and Japour AJ. Focal Mycobacterial Lymphadenitis Following Initiation of Protease Inhibitor Therapy in Patients with Advanced HIV-1 Disease. Lancet 1998; 351:252-5.

Harrich D, Hsu C, Race EM and Gaynor RB. Differential growth kinetics are exhibited by human immunodeficiency virus type I TAR mutants. J Virology 1994; 68: 5899-910.

Race EM, Ramsey KM, Lucia HL and Cloyd NM. HIV infection elicits early antibody not detected by standard tests: Implications for diagnostics and viral immunology. Virology 1991; 184: 716-22.

Reid TR, Race ER, Wolfe BR, Friedman RM, Merigan TC and Basham TY. Enhanced in vivo therapeutic response to interferon in mice with an in vitro interferon-resistant B cell lymphoma. Cancer Research 1989; 49: 4163-69.

Basham TY, Race ER, Campbell MJ, Reid TR, Levy R and Merigan TC. Synergistic antitumor activity with interferon and monoclonal anti-idiotype for murine B cell lymphoma. J Immunology 1988; 141: 2855-60.

Invited Articles

Race E, Berthelot C and Cather JC. Dermatology Report: Painful Nodule with Induration and Spreading Erythema (Community-Acquired Methicillin-Resistant Staphylococcus aureus CA-MRSA). Baylor University Medical Center Proceedings 2005; 18(4): 401-4.

Race E and Vance E. Unusual Infections in Oncology: Strongyloidiasis. Infections in Oncology 2000; 4 (3): 6-8 .

Vance E and Race E. Unusual Infections in Oncology: Coccidioidomycosis. Infections in Oncology 2000; 4 (1): 5-8.

Abstracts

Hsu A, Zolopa A, Shulman N, Havlir D, Gallant J, Race E, Jiang P, Boller S, Swerdlow J, Jasinsky O, Renz C, Japour AJ, Kempf D and Sun E. Final analysis of Ritonavir (RTV)
Kempf D, Hsu A, Jiang P, Rode R, Hertogs K, Larder B, Zolopa A, Shulman N, Havlir D, Gallant J, Race E, Boller S, Swerdlow J, Jasinsky O, Renz C and Sun E. Response to Ritonavir (RTV) Intensification in Indinavir (IDV) Recipients Is Highly Correlated with Virtual Inhibitory Quotient. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 2000; Program and Abstracts:176 ( abstract no. 523).

Shulman N, Zolopa A, Havlir D, Gallant J, Race E, Lam W, Hill A, Japour A, Kempf E, Sun E and Hsu A. Ritonavir Intensification in Indinavir Recipients with Detectable HIV RNA Levels. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 2000; Program and Abstracts: 176 (abstract no. 534).
Ritonavir Boosting of Indinavir-Based Therapy in HIV-1-infected Patients With Ongoing Viremia. International Workshop on HIV Drug Resistance & Treatment Strategies, June 12-16, 2000; abstract 95.

Ritonavir Boosting of Indinavir-Based Therapy in HIV-1-infected Patients With Ongoing Viremia. 13th World AIDS Conference, Durban, S. Africa, July 2000.

Ritonavir Boosting of Indinavir-Based Therapy in HIV-1-Infected Patients With Ongoing Viremia. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands; April 2-4, 2001; abstract 7.3.

Race E, Adelson-Mitty J, Barlam T and Japour A. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease inhibitor (PRI) in Patients with Advanced HIV-1 Disease. 4th Conference on Retroviruses and Opportunistic Infections, Washington D.C., 1997; Program and Abstracts: 129 (abstract no. 352).

Race E, Reimann K, Letvin N and Japour A. Recurrence of Trimethoprim-Sulfamethoxazole (TMP-SMX) Hypersensitivity Following Initiation of Protease Inhibitor (PRI) in Patients with Advanced HIV-1. 4th Conference on Retroviruses and Opportunistic Infections, Washington D.C., 1997; Program and Abstracts: 164 (abstract no. 535).



Love what you see?
Meet more of our amazing staff! Just scroll below.


Learn More